Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beom K Choi

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Immunology|July 5, 2007
Role of endogenous 4-1BB in the development of systemic lupus erythematosusDass S Vinay, Jae H Choi, Jung D Kim, et al.
Immunology and Cell Biology|May 20, 2003
Immunity in the absence of CD28 and CD137 (4-1BB) moleculesDass S Vinay, Godwin O Wolisi, Kang-Y Yu, et al.
Cancer Research|September 17, 2008
Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicityYoung H Kim, Beom K Choi, Kwang H Kim, et al.
Molecules and Cells|November 12, 2021
TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in LeiomyosarcomaEun-Young Lee, Minjeong Kim, Beom K Choi, et al.
Nature Communications|September 8, 2021
Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα<sup>hi</sup> CD8<sup>+</sup> T cellsSeon-Hee Kim, Eunjung Cho, Yu I Kim, et al.
Molecular Cancer Therapeutics|February 5, 2009
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapyYoung H Kim, Beom K Choi, Ho S Oh, et al.
Journal of Leukocyte Biology|March 29, 2007
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammationSu M Shin, Young H Kim, Beom K Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1Hyeon-Woo Lee, Su-Jung Park, Beom K Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responsesDass S Vinay, Beom K Choi, Jun S Bae, et al.
Cancers|August 28, 2020
Midkine Is a Potential Therapeutic Target of Tumorigenesis, Angiogenesis, and Metastasis in Non-Small Cell Lung CancerDong Hoon Shin, Jeong Yeon Jo, Sun Ha Kim, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Immunology|July 5, 2007
Role of endogenous 4-1BB in the development of systemic lupus erythematosusDass S Vinay, Jae H Choi, Jung D Kim, et al.
Immunology and Cell Biology|May 20, 2003
Immunity in the absence of CD28 and CD137 (4-1BB) moleculesDass S Vinay, Godwin O Wolisi, Kang-Y Yu, et al.
Cancer Research|September 17, 2008
Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicityYoung H Kim, Beom K Choi, Kwang H Kim, et al.
Molecules and Cells|November 12, 2021
TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in LeiomyosarcomaEun-Young Lee, Minjeong Kim, Beom K Choi, et al.
Nature Communications|September 8, 2021
Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα<sup>hi</sup> CD8<sup>+</sup> T cellsSeon-Hee Kim, Eunjung Cho, Yu I Kim, et al.
Molecular Cancer Therapeutics|February 5, 2009
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapyYoung H Kim, Beom K Choi, Ho S Oh, et al.
Journal of Leukocyte Biology|March 29, 2007
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammationSu M Shin, Young H Kim, Beom K Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1Hyeon-Woo Lee, Su-Jung Park, Beom K Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responsesDass S Vinay, Beom K Choi, Jun S Bae, et al.
Cancers|August 28, 2020
Midkine Is a Potential Therapeutic Target of Tumorigenesis, Angiogenesis, and Metastasis in Non-Small Cell Lung CancerDong Hoon Shin, Jeong Yeon Jo, Sun Ha Kim, et al.
Pageof 7